Barclays PLC Acquires 104,420 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Barclays PLC increased its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 214.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 153,039 shares of the company's stock after purchasing an additional 104,420 shares during the period. Barclays PLC owned approximately 0.26% of Twist Bioscience worth $6,913,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Caprock Group LLC increased its position in shares of Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company's stock valued at $387,000 after buying an additional 220 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares in the last quarter. Arizona State Retirement System raised its position in shares of Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock worth $798,000 after purchasing an additional 308 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock valued at $457,000 after purchasing an additional 312 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Twist Bioscience by 2.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock worth $734,000 after purchasing an additional 363 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TWST shares. Robert W. Baird increased their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 19th. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price on the stock. Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, November 19th. Finally, Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $51.90.

Twist Bioscience Trading Down 2.2 %

Shares of TWST traded down $0.99 during midday trading on Thursday, reaching $43.62. The stock had a trading volume of 969,147 shares, compared to its average volume of 940,619. The firm has a 50 day simple moving average of $45.18 and a 200-day simple moving average of $46.80. The firm has a market cap of $2.59 billion, a PE ratio of -12.12 and a beta of 1.82. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Insider Buying and Selling

In other news, SVP Paula Green sold 860 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the transaction, the senior vice president now directly owns 133,715 shares of the company's stock, valued at $7,046,780.50. This represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 2,216 shares of Twist Bioscience stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $116,783.20. Following the sale, the chief executive officer now directly owns 674,718 shares of the company's stock, valued at $35,557,638.60. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 101,920 shares of company stock worth $4,590,734. Company insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.